Phase 2 N=69 Chemoradiation and Tetrathiomolybdate (TM) in Patients With Esophageal Carcinoma
Esophageal Carcinoma
Primary: Median Recurrence Free Survival Time — 23.1 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=123 Relation Between NLR and IMR in STEMI Patients
Myocardial Infarction · Death
Primary: Index of Microcirculatory Resistance — 21.94; 23.22; 32.95 IMR
Phase 4 N=8 Study of the Presence and Extent of Corneal Disturbance Associated With B+L Biotrue MPS Used With B+L PureVision Lenses
Keratitis
Primary: Number of Participants Wiith Corneal Staining — 1; 6 participants
N/A N=40 Comparison of Flexible Fibreoptic Scope With Pentax AWS Videolaryngoscope for Ease of Intubation During Awake Intubation
Anesthesia Intubation Complication
Primary: Total Time Taken to Complete the Procedure of Awake Intubation — 900; 651 seconds
N/A N=90 An Observational Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis And Inadequate Response Or Intolerance to a First Anti-TNF Alpha Therapy
Rheumatoid Arthritis
Primary: Efficacy: Mean Change From Baseline in DAS28 at Month 6 in Intention to Treat (ITT) Population — 6.35; 5.54; -1.89; -1.80 units on a scale — p=0.3037
Phase 1 N=30 Food-Effect Study in Healthy Participants
Healthy
Primary: Pharmacokinetics - Cmax (ng/mL) — 394.7; 322.8 ng/mL
Phase 1 N=14 Phase 1 Bioavailability Study of Apixaban Solution Formulation Relative to Apixaban Tablets in Healthy Subjects
Healthy Volunteers
Primary: Adjusted Geometric Mean of the Maximum Observed Plasma Concentration (Cmax) of Apixaban — 293.994; 287.164 ng/mL
Phase 2 N=162 A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
Primary: Phase 1: To Determine the Recommended Phase 2 Dose of the MM-121 + Erlotinib Combination Based Upon Either the Maximum Tolerated Dose (MTD) or the Maximum Feasible Dose…
N/A N=22 Effects of LEDs on Memory in TBI Patients
Traumatic Brain Injury
Primary: Stroop Test for Executive Function - Trial 3 - Inhibition — -0.7407; .036; .718; .815 # of SD units — p=<0.004
Phase 3 N=377 This is an Open-label, Multi-center, Extension Study Designed to Evaluate the Longer Term Safety, Tolerability and Effectiveness of Lurasidone, Flexibly Dosed, Adjunctive to Lithium or Divalproex for the Treatment of Subjects With Bipolar I Disorder Who Have Participated in Study D1050296
Bipolar I Disorder
Primary: Treatment-emergent Adverse Events and Treatment-emergent Adverse Events Leading to Discontinuation and Serious Adverse Events — 155; 69; 14; 1 participants
Phase 4 N=124 Safety and Efficacy of Lubiprostone in Pediatric Patients With Constipation
Constipation
Primary: Frequency of Spontaneous Bowel Movements — 2.47; 3.02; 3.84 spontaneous bowel movements per week
Phase 3 N=239 Efficacy and Safety of Adalimumab in Patients With Active Uveitis
Uveitis
Primary: Time to Treatment Failure on or After Week 6 — 3.0; 5.6; 3.0; 4.8 months — p=<0.001
Phase 1 N=19 Pharmacokinetics of rFVIIIFc at Two Vial Strengths
Severe Hemophilia A
Primary: Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf) as Measured by Activated Partial Thromboplastin Time (aPTT) Clotting Assay — 2888.9; 2646.3…
Phase 2 N=158 A Study of Xeloda (Capecitabine) in Combination With Chemotherapy in Patients With Advanced and/or Metastatic Gastric Cancer.
Gastric Cancer
Primary: Percentage of Participants With Grade 3 Hand-Foot Syndrome (HFS) — 2.4; 6.3; 3.7; 5.2 percentage of participants
Phase 2 N=11 A Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL)
Lymphoma, T-cell, Peripheral
Primary: Number of Participants With Dose-limiting Toxicity (DLT) in Accordance With National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)…